Search Results
10 results for cancer
New Strategies For Public Health Genomics Beyond Newborn Screening
A Working Meeting and an Action Plan to Save Lives Now Nearly 2 million Americans are affected by one of three genetic conditions with a strong risk of early morbidity and mortality: BRCA 1/2 and hereditary breast and ovarian cancer; Lynch syndrome and colorectal , endometrial and ovarian cancer; and familial hypercholesterolemia and early cardiovascular events. At
Posted on by 2 CommentsEvidence Matters in Genomic Medicine—Round 3: Integrating Family Health History into Clinical Preventive Services
A new podcast from the CDC Expert Commentary Series on Medscape—Family Health History: Use It to Inform Preventive Services for Your Patients— describes how family health history can inform the delivery of preventive health services. The podcast presents three case studies based on recommendations of the US Preventive Services Task Force (USPSTF): screening for lipid
Posted on byMore Workings of an Evidence-Based Genomic Panel: Modernizing the Evidence Review Process
The independent EGAPP working group (EWG) held its 25th meeting on September 10-11, 2012 at the CDC campus in Atlanta. Highlights included: Three EWG recommendation statements on the validity and utility of genetic tests are pending publication on: KRAS, BRAF and other markers involved in EGFR signaling, which are used to inform choice of therapies for
Posted on byWhat Gets Measured Gets Done: Genomics, Surveillance Indicators and Healthy People 2020
Public health surveillance indicators, such as those developed for the Healthy People initiative are useful for monitoring the development of genomic medicine in the United States. For several decades, Healthy People has established health benchmarks that are considered important metrics for tracking progress in health and healthcare in the United States.
Posted on byPeeling the Pyramid, Scaling the Onion—How to Implement Genomic Medicine
In spite of the promise of genomics and related technologies for a new era of precision healthcare and disease prevention, only a handful of genomic tests and applications have been recommended for use in clinical practice. Nevertheless, implementation of even the few recommended genomic tests is lagging. For example, implementing the 2005 USPSTF recommendation on genetic
Posted on byWorkings of an Evidence-Based Genomic Panel
Synopsis of the 24th Meeting of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group The EGAPP working group (EWG) has held 24 meetings in the 7 years since they were first convened; the latest EGAPP meeting was May 7-8, 2012 on the campus of CDC in Atlanta. Since it is
Posted on bySmoke Screen…
Never Let Genetics Blind You to the Harsh Reality of Cigarettes The emerging field of genomics might one day provide some tools to help address the smoking epidemic. However, smokers should never think that their genes can protect them from devastating harms or provide an easy way for them to quit later. In 2012,
Posted on byEvidence Matters in Genomic Medicine
A new IOM report makes recommendations that aim to ensure that progress in omics-based test development is grounded in sound scientific evidence and is reproducible, resulting in improved health care and continued public trust in research. Another new IOM roundtable workshop report discussed the differences in evidence required for clinical use, regulatory oversight, guideline inclusion, coverage,
Posted on by 1 CommentMaking Universal Screening for Lynch Syndrome a Reality: The Lynch Syndrome Screening Network
Every day, about 400 people in the United States are diagnosed with colorectal cancer. Approximately twelve of them have Lynch syndrome, a hereditary condition that increases the risk of colorectal cancer and other cancers. Identifying people with Lynch syndrome could have substantial health benefits for them, their families, and communities.
Posted on by 1 CommentThe Public Health Approach to Genetic Testing in the 21st Century: Saving Lives and Saving Unnecessary Healthcare Costs
In March 2012, a prominent health insurer in the United States released a white paper entitled: “Personalized Medicine: trends and prospects for the new science of genetic testing and molecular diagnostics” By analyzing their own claims data, the report suggests that in 2010, the cost of genetic and molecular diagnostic testing for its members was about $500
Posted on by 4 Comments